Citius Oncology Deploys AI Platform for LYMPHIR Launch

Citius Oncology has deployed an AI platform to bolster its commercial team's capabilities in preparation for the launch of LYMPHIR, a novel therapy for cutaneous T-cell lymphoma (CTCL). announced in a press release, the platform is designed to enhance decision-making and targeting strategies by providing advanced data analytics and insights.

The proprietary AI system identifies treatment and diagnosis patterns, allowing the commercial team to target prescribers whose patients may benefit from LYMPHIR. It employs machine learning to continuously improve its targeting precision, thereby supporting informed patient care.

The AI platform integrates real-world U.S. claims data and marketing performance analytics, adapting over time to deliver predictive insights. This enables dynamic content sequencing and tailored customer journeys across digital and in-person interactions, optimizing the commercial infrastructure and enhancing healthcare provider education.